Great Entry below 2 imo for 1 year hold ZTlido is a branded, non-aqueous, topical lidocaine patch for pain
associated with post-herpetic neuralgia
› Benefits vs. market leader, Lidoderm®, and other pain patches
o Thin, pliable non-aqueous patch w/ 36 mg of drug to deliver
therapeutic dose vs. Lidoderm, a thick, aqueous patch w/ 700 mg
of drug to deliver therapeutic dose
o Greater adhesion to the skin based on multiple adhesion studies
̶ 90% adhesion in 90% of subjects over 12 hours (no marketed
patches have such data)
̶ No meaningful impact to PK during and after exercise
o Less drug required to administer therapeutic dose, provides cost
advantage in a largely genericized market
› US pain patch market(1) = ~$700mm in 2015
o Potential tailwind from significant demand for abuse-deterrent
alternatives for pain management
› NDA resubmission expected in mid 2017, with potential approval
in 2H17 (2 to 6 month review)
http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
|
|
|
2.53
0.42
